← Back
Data updated: Jul 17, 2026
NORVIUM BIOSCIENCE
Specialty Pharmaceuticals
NORVIUM BIOSCIENCE is a specialty pharmaceutical company with 4 FDA-approved products.
1958
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
NORVIUM BIOSCIENCE's Key Drugs
NORVIUM BIOSCIENCE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
NORVIUM BIOSCIENCE's Recent FDA Approvals
New NDA/BLA approvals for NORVIUM BIOSCIENCE over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NORVIUM BIOSCIENCE's Therapeutic Areas
Disease areas where NORVIUM BIOSCIENCE has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NORVIUM BIOSCIENCE Pipeline Snapshot
Active clinical trials for NORVIUM BIOSCIENCE across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1958-10-23
- Latest
- 2022-05-18
- Applications
- 4